Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials | Zendy

Emerson Y. Chen | Zendy; Sunil K. Joshi | Zendy; Audrey Tran | Zendy; Vinay Prasad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

Author(s) -

Emerson Y. Chen,

Sunil K. Joshi,

Audrey Tran,

Vinay Prasad

Publication year - 2019

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2018.8351

Subject(s) - medicine , surrogate endpoint , clinical trial , oncology , clinical endpoint , progression free survival , sample size determination , quality of life (healthcare) , overall survival , statistics , mathematics , nursing

Surrogate end points in oncology trade the advantage of reducing the time needed to conduct clinical trials for the disadvantage of greater uncertainty regarding the treatment effect on patient-centered end points, such as overall survival (OS) and quality of life.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research